Becton Dickinson & Co (WBO:BDX)
€ 210.4 -0.6 (-0.28%) Market Cap: 60.75 Bil Enterprise Value: 77.74 Bil PE Ratio: 37.36 PB Ratio: 2.48 GF Score: 82/100

Becton Dickinson and Co at Morgan Stanley Healthcare Conference Transcript

Sep 11, 2019 / 01:20PM GMT
Release Date Price: €230.86 (+2.41%)
David Ryan Lewis
Morgan Stanley, Research Division - MD

Okay. Well, thank you for that. So as we progress through the morning, my name is David Lewis, medical device analyst here at Morgan Stanley. It's my pleasure to have with us here 2 members of management from Becton, Dickinson, both Vince Forlenza, the Chairman and CEO; and Chris Reidy, EVP and CFO.

And so we're going to get right -- no preamble for you, Vince. We'd just get right into it.

Vincent A. Forlenza
Becton, Dickinson and Company - Chairman & CEO

We can get right into it.

Questions & Answers

David Ryan Lewis
Morgan Stanley, Research Division - MD

Sweet. So I'm going to start strategic, Vince, and kind of work my way into the tactical with you and Chris. I guess the first thing is we've been here through a lot of years. We've been here through the CareFusion years, we've been here through the Bard years. Look, CareFusion was -- of the 5 transformational deals in medical devices, CareFusion is the only transaction of the big 5

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot